Biopharma Sizes Up The Affordable Care Act: Buyer’s Remorse Or Winner’s Curse?

Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.

Three years into the Patient Protection and Affordable Care Act (ACA), the biopharma industry, like much of corporate America, is struggling to assess whether it gains from the Act or loses. The negatives for pharma are clear: givebacks to the federal government of tens of billions of dollars a year. Harder to gauge have been the potential benefits, notably those stemming from the Act’s biggest and most visible initiatives – the health insurance exchanges (HIXs) and expansion of Medicaid coming on line January 1, 2014 that will provide insurance to currently uninsured adults.

When Congress passed the legislation in March 2010, the Congressional Budget Office (CBO) projected it would enable 35 million previously...

More from Business Strategy

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.